J Rheum Dis.  2014 Aug;21(4):176-181. 10.4078/jrd.2014.21.4.176.

Update on the Treatment of Intestinal Behcet's Disease

Affiliations
  • 1Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. capsulendos@gmail.com

Abstract

Behcet's disease is a chronic relapsing disease with unknown etiology, involving the multiorgan system characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmologic, neurologic, or gastrointestinal manifestations (or some combination of these). Since intestinal Behcet's disease has been treated anecdotally with various therapeutic modalities, clinical evidence regarding the management of intestinal Behcet's disease is still lacking. 5-aminosalycylic acid, corticosteroids, immunosuppressants, and surgical therapy have been considered as traditional therapies for intestinal Behcet's disease. The treatment with thalidomide and anti-TNF agents, such as infliximab or adalimumab, is increasing. Future clinical trials are still needed.

Keyword

Intestine; Behcet's disease

MeSH Terms

Adrenal Cortex Hormones
Adalimumab
Infliximab
Immunosuppressive Agents
Intestines
Stomatitis, Aphthous
Thalidomide
Adrenal Cortex Hormones
Immunosuppressive Agents
Thalidomide
Full Text Links
  • JRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr